Matinas BioPharma Appoints Matthew A. Wikler, M.D., M.B.A., F.I.D.S.A., to Board of Directors
December 14 2017 - 7:01AM
Matinas BioPharma Holdings, Inc. (NYSE MKT:MTNB), a clinical-stage
biopharmaceutical company focused on developing innovative
anti-infectives for orphan indications, announced the appointment
of Matthew A. Wikler, M.D., M.B.A., FIDSA, to its Board of
Directors. Dr. Wikler will replace current Board member, Stefano
Ferrari, effective January 1, 2018.
Dr. Wikler is a senior healthcare physician
executive and therapeutic expert in infectious diseases, who has
successfully and ethically developed multiple pharmaceutical
products in the biopharmaceutical industry over the past
thirty-three years of his career. He joins the Matinas Board with
broad experience in strategically positioning technology through
scientifically and commercially assessing products and building
leading teams that have a passion for developing drugs that are
aligned with the commercialization process to benefit patients.
Over the course of his career, Dr. Wikler played a significant role
in the U.S. Food and Drug Administration (“FDA”) filing and
subsequent approval for 20 different compounds in systemic
antibiotics, topical antibiotics, systemic antivirals and
vaccines.
“We are incredibly pleased to welcome Dr.
Wikler, a preeminent infectious disease product development expert,
to our Board. Dr. Wikler’s track record in this space is
impressive, and we look forward to leveraging his expertise as we
develop and advance product candidates based upon our proprietary
cochleate drug delivery platform,” commented Herb Conrad, Chairman
of the Board of Matinas. “Additionally, we are sincerely grateful
to Mr. Ferrari for his years of service to Matinas. He joined the
Board of Directors in 2012 as a founding member and has been an
integral member of the Company, providing invaluable insight and
leadership over the years.”
Dr. Wikler currently serves as the Principal of
Infectious Disease Technology Development Consulting (IDTD
Consulting) where he provides clinical, medical and regulatory
strategic insight to companies developing new technologies for the
treatment and prevention of infectious diseases. Prior to that from
2012 to 2015, Dr. Wikler served at The Medicines Company (NASDAQ:
MDCO) as VP, New Business Ventures and VP and Medical Director,
Infectious Disease Care. During his time at The Medicines Company,
Dr. Wikler was responsible for leading the clinical and medical
teams and providing strategic direction for the US and EU clinical
development and regulatory activities for oritavancin, which
resulted in its approval in both the US and EU. Over the course of
his career Dr. Wikler held senior leaderships positions for a
number of pharmaceutical companies, including as Chief Development
Officer of Rib-X Pharmaceuticals, President and Chief Executive
Officer of IASO Pharma Inc., a clinical stage biotechnology company
focused on the development of antibacterial and antifungal
therapeutics, the Institute for One World Health, Mpex
Pharmaceuticals, Peninsula Pharmaceuticals (acquired by Johnson
& Johnson), ViroPharma, Bristol-Myers Squibb Company, and
Ortho-McNeil Pharmaceutical (a division of Johnson & Johnson).
Dr. Wikler began his career at Smith Kline & French/Smith Kline
Beecham where he held positions of increasing responsibilities over
ten years. Dr. Wikler held a variety of positions at the FDA,
including the Deputy Director of the Division of Anti-Infective
Drug Products.
Dr. Wikler earned a B.A. in Chemistry from
Franklin and Marshall, an M.D. degree from Temple University School
of Medicine, and his M.B.A. from the University of Pennsylvania
Wharton School of Business. He completed his Infectious Diseases
Fellowship at the Hospital of the University of Pennsylvania and is
a Fellow of the Infectious Diseases Society of America.
About Matinas BioPharma
Matinas BioPharma is a clinical-stage
biopharmaceutical company focused on developing innovative
anti-infectives for orphan indications. The Company's proprietary,
disruptive technology utilizes lipid-crystal nano-particle
cochleates to nano-encapsulate existing drugs, making them safer,
more tolerable, less toxic and orally bioavailable.
The Company's lead anti-infective product
candidates, MAT2203 and MAT2501, position Matinas BioPharma to
become a leader in the safe and effective delivery of
anti-infective therapies utilizing its proprietary lipid-crystal
nano-particle cochleate formulation technology. For more
information, www.matinasbiopharma.com and connect with the Company
on Twitter, LinkedIn, Facebook, and Google+.
Forward Looking Statements:
This release contains "forward-looking statements" within the
meaning of the Private Securities Litigation Reform Act of 1995,
including those relating to the Company's strategic focus and the
future development of its product candidates, including MAT2203 and
MAT2501, the anticipated timing of regulatory submissions, the
anticipated timing of clinical studies, the Company’s ability to
identify and pursue development and partnership opportunities for
its products or platform delivery technology on favorable terms, if
at all, and the ability to obtain required regulatory approval and
other statements that are predictive in nature, that depend upon or
refer to future events or conditions. All statements other than
statements of historical fact are statements that could be
forward-looking statements. Forward-looking statements include
words such as "expects," "anticipates," "intends," "plans,"
"could," "believes," "estimates" and similar expressions. These
statements involve known and unknown risks, uncertainties and other
factors which may cause actual results to be materially different
from any future results expressed or implied by the forward-looking
statements. Forward-looking statements are subject to a number of
risks and uncertainties, including, but not limited to, our ability
to obtain additional capital to meet our liquidity needs on
acceptable terms, or at all, including the additional capital which
will be necessary to complete the clinical trials of our product
candidates; our ability to successfully complete research and
further development and commercialization of our product
candidates; the uncertainties inherent in clinical testing; the
timing, cost and uncertainty of obtaining regulatory approvals; our
ability to maintain and derive benefit from the Qualified
Infectious Disease Product (QIDP), Orphan and/or Fast Track
designations for MAT2203 and MAT2501, which does not change the
standards for regulatory approval or guarantee regulatory approval
on an expedited basis, or at all; our ability to protect the
Company's intellectual property; the loss of any executive officers
or key personnel or consultants; competition; changes in the
regulatory landscape or the imposition of regulations that affect
the Company's products; and the other factors listed under "Risk
Factors" in our filings with the SEC, including Forms 10-K, 10-Q
and 8-K. Investors are cautioned not to place undue reliance on
such forward-looking statements, which speak only as of the date of
this release. Except as may be required by law, the Company does
not undertake any obligation to release publicly any revisions to
such forward-looking statements to reflect events or circumstances
after the date hereof or to reflect the occurrence of unanticipated
events. Matinas BioPharma's product candidates are all in a
development stage and are not available for sale or use.
Investor ContactJenene ThomasJenene Thomas
Communications, LLCPhone: +1 (908) 938-1475Email:
jenene@jenenethomascommunications.com
Source: Matinas BioPharma Holdings, Inc.
Matinas Biopharma (AMEX:MTNB)
Historical Stock Chart
From Aug 2024 to Sep 2024
Matinas Biopharma (AMEX:MTNB)
Historical Stock Chart
From Sep 2023 to Sep 2024